Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 27, 2017

Study Completion Date

December 27, 2017

Conditions

Neoplasms

Interventions

DRUG

sorafenib

In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib

Trial Locations (1)

VU University Medical Center, Amsterdam

All Listed Sponsors

lead

Amsterdam UMC, location VUmc

OTHER

NCT02636426 - Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study | Biotech Hunter | Biotech Hunter